Pharma — Juli 2023
-
Johnson & Johnson Poised For A Muted Q2? https://www.proinvestor.com/investornyt/1015967/johnson-amp-johnson-poised-for-a-muted-q2
-
New Alzheimer’s Drug Is First to Show It Slows Disease. But It’s Facing a Rocky Rollout https://firstwordpharma.com/story/5761407
-
Drugs Like Ozempic Created a Gold Rush. These Drugmakers Want In. https://firstwordpharma.com/story/5761397
-
Acadia Pharmaceuticals Rights Deal and Bullish Outlook Sends Shares Surging 16%. Here’s What To Expect
17/7 10:18
In a stunning two-day rally, shares of Acadia Pharmaceuticals (US:ACAD) have seen a 16% surge following the announcement of the company's acquisition of expanded commercial rights for the groundbreaking Rett syndrome drug, trofinetide. https://www.proinvestor.com/investornyt/1016000/acadia-pharmaceuticals-rights-deal-and-bullish-outlook-sends-shares-surging-16-heres-what-to-expect
-
Acadia (ACAD) Soars 24.7%: Is Further Upside Left in the Stock? https://www.proinvestor.com/investornyt/1015999/acadia-acad-soars-247-is-further-upside-left-in-the-stock
-
Eli Lilly med positivt resulat af Alzheimers-forsøg https://www.proinvestor.com/investornyt/1016270/eli-lilly-med-positivt-resulat-af-alzheimers-forsog
-
Schweizisk Genmab-partner opjusterer efter overbevisende kvartal https://www.proinvestor.com/investornyt/1016615/schweizisk-genmab-partner-opjusterer-efter-overbevisende-kvartal
-
Cantor Fitzgerald Reiterates Lilly (LLY) Overweight Recommendation https://www.proinvestor.com/investornyt/1016612/cantor-fitzgerald-reiterates-lilly-lly-overweight-recommendation
-
Lilly Says Its Alzheimer's Drug Significantly Slowed Cognitive And Functional Decline https://www.proinvestor.com/investornyt/1016637/lilly-says-its-alzheimers-drug-significantly-slowed-cognitive-and-functional-decline
-
JP Morgan Maintains Johnson & Johnson (JNJ) Neutral Recommendation https://www.proinvestor.com/investornyt/1019609/jp-morgan-maintains-johnson-amp-johnson-jnj-neutral-recommendation
-
Credit Suisse Maintains Johnson & Johnson (JNJ) Neutral Recommendation https://www.proinvestor.com/investornyt/1019608/credit-suisse-maintains-johnson-amp-johnson-jnj-neutral-recommendation
-
Morgan Stanley Reiterates Johnson & Johnson (JNJ) Equal-Weight Recommendation https://www.proinvestor.com/investornyt/1019610/morgan-stanley-reiterates-johnson-amp-johnson-jnj-equal-weight-recommendation
-
GSK : ViiV's Cabotegravir For HIV Prevention Receives Positive CHMP Opinion From EMA https://www.proinvestor.com/investornyt/1019886/gsk-viivs-cabotegravir-for-hiv-prevention-receives-positive-chmp-opinion-from-ema
-
Sandoz Obtains Positive CHMP Opinion For Multiple Sclerosis Biosimilar Natalizumab https://www.proinvestor.com/investornyt/1019879/sandoz-obtains-positive-chmp-opinion-for-multiple-sclerosis-biosimilar-natalizumab
-
Dagens aktie er Regeneron
Pharmaceuticals Inc.Regeneron Pharmaceuticals, Inc. er en amerikansk bioteknologivirksomhed der forsker, udvikler, fabrikerer og klargør medicin til markedet https://proinvestor.com/boards/114238/
-
Roche tynget af svindende efterspørgsel på coronamidler i første halvår
https://www.proinvestor.com/investornyt/1022152/roche-tynget-af-svindende-eftersporgsel-pa-coronamidler-i-forste-halvar -
Japansk Lundbeck-partner leverer over forventning https://www.proinvestor.com/investornyt/1022171/japansk-lundbeck-partner-leverer-over-forventning
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind